发行人：苏州丰倍生物科技股份有限公司 保荐人（主承销商）：国泰海通证券股份有限公司 2025年10月31日 苏州丰倍生物科技股份有限公司（以下简称"丰倍生物""发行人"或"公司"）首次公开发行股票并在主板 上市的申请已经上海证券交易所（以下简称"上交所"）上市审核委员会审议通过，并已经中国证券监督 管理委员会（以下简称"中国证监会"）证监许可〔2025〕1958号文同意注册。《苏州丰倍生物科技股份 有限公司首次公开发行股票并在主板上市招股说明书》及附录在上海证券交易所网站 （www.sse.com.cn）和符合中国证监会规定条件网站（中国证券网，网址www.cnstock.com；中证网， 网址www.cs.com.cn；证券时报网，网址www.stcn.com；证券日报网，网址www.zqrb.cn；经济参考网， 网址www.jjckb.cn；金融时报，网址www.financialnews.com.cn；中国日报，网址 www.chinadaily.com.cn）披露，并置备于发行人、本次发行保荐人（主承销商）国泰海通证券股份有限 公司的住所，供公众查阅。 ■■ ...

Core Points - The application for the initial public offering (IPO) of Suzhou Fengbei Biotechnology Co., Ltd. has been approved by the Shanghai Stock Exchange and registered by the China Securities Regulatory Commission [1][2] - The IPO price is set at 24.49 yuan per share, with a total issuance of 35.9 million shares, all of which are new shares [2][3] - The strategic placement accounts for 20% of the total issuance, with the final strategic placement amounting to 11.37% after adjustments [3][4] Issuance Details - The issuance combines strategic placement, offline pricing for qualified investors, and online issuance for public investors [2] - The final number of shares for offline issuance is 7,601,703, while online issuance amounts to 24,215,000 shares [4][8] - The overall subscription rate for online issuance reached 8,814.92 times, prompting a mechanism to adjust the allocation between offline and online investors [3][4] Subscription Statistics - Total shares subscribed by online investors: 24,089,076 shares, with a total subscription amount of approximately 589.94 million yuan [8] - Total shares subscribed by offline investors: 7,601,703 shares, with a total subscription amount of approximately 186.17 million yuan [9] - No shares were abandoned by offline investors, while online investors abandoned 125,924 shares [8][9] Lock-up Period and Underwriting - Offline investors are subject to a lock-up period of 6 months for 10% of their allocated shares [10] - The underwriter, Guotai Junan Securities, will underwrite all shares that were abandoned during the subscription process, totaling 125,924 shares [11][12] Issuance Costs - Total issuance costs amount to approximately 84.75 million yuan, including underwriting fees, audit fees, legal fees, and other expenses [13]

两融数据显示，该股最新融资余额为3.16亿元，近5日增加582.89万元，增幅为1.88%。 欧林生物10月30日大宗交易平台共发生9笔成交，合计成交量192.60万股，成交金额3713.32万元。成交价格均为19.28元，相对今日收盘价折价17.99%。从参与大宗交易营业部来看，机构 进一步统计，近3个月内该股累计发生27笔大宗交易，合计成交金额为1.34亿元。 证券时报·数据宝统计显示，欧林生物今日收盘价为23.51元，下跌2.16%，日换手率为1.45%，成交额为1.41亿元，全天主力资金净流入1458.63万元，近5日该股累计上涨3.25%，近5日资 据天眼查APP显示，成都欧林生物科技股份有限公司成立于2009年12月11日，注册资本40593.36万人民币。（数据宝） 10月30日欧林生物大宗交易一览 ...

Group 1 - The company, BioShares, completed a share buyback on October 29, 2023, repurchasing approximately 15.71 million shares, which accounts for 1.4134% of its total share capital [1] - The buyback was executed through centralized bidding, with the highest transaction price at 8.97 CNY per share, the lowest at 6.37 CNY per share, and an average buyback price of 6.9 CNY per share, totaling approximately 108 million CNY in funds used [1] - For the fiscal year 2024, the company's revenue composition is as follows: biopharmaceuticals account for 94.42%, other industries for 3.18%, and other businesses for 2.4% [1]

美佑恒®(注射用维贝柯妥塔单抗)在既往经治过二线及以上系统性化疗及PD-(L)1抑制剂失败后的患者中 显示出临床意义的疗效优势，同时安全性可控。美佑恒®(注射用维贝柯妥塔单抗)用于治疗R/MNPC的 关键注册性临床研究结果于2025年美国临床肿瘤学会年会上以"重磅研究摘要(LBA)"形式公布，并于会 上作口头报告。 此外，美佑恒®(注射用维贝柯妥塔单抗)与普佑恒(普特利单抗注射液)的联合疗法呈现显著且持久的临 床效益，在该联用治疗的II期临床试验中，针对免疫治疗及铂类化疗失败的患者中实现了迄今为止最高 的确认客观缓解率(cORR)(73.3%，95%CI:54.1-87.7)及最长的无进展生存期(mPFS)(10.9m，95%CI:6.6- 15.4)，有望为抗PD-(L)1及铂类化疗失败的R/MNPC患者提供更为有效的治疗选择。上述数据已在2025 年欧洲肿瘤内科学会年会上公布。 格隆汇10月30日丨乐普生物-B(02157.HK)公告，董事会欣然宣布国家药品监督管理局("国家药监局")近 期批准候选药物美佑恒®(注射用维贝柯妥塔单抗)在中国的上市申请，该药物为公司自主研发的一种表 皮生长因子受体("EGF ...

Group 1 - The inclusion of the HPV vaccine in the national immunization program marks a significant breakthrough in public health in China, with over 10 million eligible girls expected to benefit annually from the free vaccination policy starting November 10, 2025 [1][2] - The two-valent HPV vaccine can prevent approximately 70% of cervical cancer cases, which is a major advancement in cervical cancer prevention [1][5] - The market demand for HPV vaccines is projected to reach tens of millions of doses annually, with the market size expected to exceed 10 billion RMB, indicating a substantial growth opportunity for domestic vaccine manufacturers [1][5][6] Group 2 - The government has allocated a budget of approximately 425 million RMB for the centralized procurement of the two-valent HPV vaccine, with an estimated procurement price of 27.5 RMB per dose [5] - The total market size for the national immunization program from 2025 to 2030 is estimated to be around 3.8 billion RMB, which includes both new eligible girls and existing populations needing booster shots [5][6] - The policy is expected to enhance public awareness and willingness to receive HPV vaccinations, potentially increasing demand for self-paid vaccinations among other age groups [5][6] Group 3 - Domestic vaccine companies such as Wantai Biological Pharmacy and Watson Bio are leading the charge in the HPV vaccine market, with significant advancements in technology and production capacity [6][8] - Wantai Biological's two-valent HPV vaccine was the first domestically produced vaccine to break the monopoly of imported vaccines, and the company has also developed the first nine-valent HPV vaccine in China [8][9] - The competition among domestic companies is expected to ensure supply security and drive technological innovation, while also reducing costs and enhancing industry safety and self-sufficiency [9]

Core Insights - NovoCure reported revenue of $167.2 million for the quarter ended September 2025, reflecting a year-over-year increase of 7.8% and a positive surprise of 5.76% over the Zacks Consensus Estimate of $158.1 million [1] - The company's EPS was -$0.33, which is a decline from -$0.28 in the same quarter last year, but it exceeded the consensus estimate of -$0.42 by 21.43% [1] Financial Performance - The revenue growth of 7.8% indicates a solid performance compared to the previous year [1] - The EPS surprise of +21.43% suggests better-than-expected performance in terms of profitability [1] Geographic Revenue Breakdown - Revenue from Greater China was $5.6 million, surpassing the average estimate of $3.65 million [4] - Revenue from Japan reached $9.39 million, slightly above the average estimate of $9.12 million [4] - Revenue from the United States was $96.61 million, exceeding the average estimate of $95.13 million [4] Stock Performance - NovoCure's shares have returned -3.6% over the past month, contrasting with the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Summary of Changchun High-tech Conference Call Company Overview - **Company**: Changchun High-tech - **Date**: October 30, 2025 Key Points Financial Performance - **Overall Revenue**: Approximately 9.8 billion RMB, with a profit of about 1.165 billion RMB [3] - **Jinsai Pharmaceutical**: Revenue remained stable at 8.213 billion RMB, profit down by approximately 50% [3] - **Baike Pharmaceutical**: Revenue impacted by the return of shingles vaccine, down 53% to about 474 million RMB, resulting in a loss of approximately 158 million RMB [2][3] - **Traditional Chinese Medicine Segment**: Revenue slightly decreased to 542 million RMB, but profit increased by 2% to 36 million RMB [3] - **Real Estate Segment**: Revenue decreased by 8% to 544 million RMB, maintaining a slight profit [3] Product Pipeline and Market Strategy - **Medicare National Negotiation Participation**: Products include long-acting growth hormone Jinsai Zeng, Meishiya, and Children's Golden Granules, with decisions based on pricing [2][5] - **Innovative Drug Pipeline**: Products like NK422 and NK27 have shown preliminary clinical data, with expectations for rapid growth in business development (BD) from 2026 to 2028 [2][6] - **Sales Performance of New Products**: Strong sales momentum for Fuxing Umbilical Monoclonal Antibody, Meishiya, and Children's Golden Granules [2][6] - **Allergy Treatment Collaboration**: Partnership with LK for dust mite desensitization treatment, with plans to establish allergy desensitization centers in major pediatric hospitals [2][7] Clinical Trials and Development - **PD-1 Agonist**: Currently in Phase I clinical trials, with plans for Phase II trials following data disclosure [13] - **Clinical Progress of Meishiya**: Used for cancer anorexia and cachexia treatment, currently enrolling for clinical trials [11] - **Growth Hormone Monthly Formulation**: Adult SAD trials progressing well, transitioning to pediatric CAD trials expected soon [11] Market Challenges and Opportunities - **Non-Entry into Medicare for Jinsai Zeng**: Decision based on anticipated unreasonable pricing from the government; plans to negotiate with commercial insurance [12][14] - **Sales Team Expansion**: Sales team has grown to over 200 members, aiming to cover more than 1,500 hospitals [10][17] - **Focus on Respiratory and Allergy Treatments**: Targeting major diseases like cystic fibrosis and chronic obstructive pulmonary disease (COPD) with innovative products [19] Future Outlook - **Growth Potential**: Despite short-term challenges, long-term growth potential remains strong, especially in innovative drug development and market expansion [21][24] - **Hong Kong Listing Progress**: Normal progress with documents submitted by September 30, aiming for successful issuance next year [22] - **Clinical Pipeline**: 41 clinical pipelines in development, focusing on maximizing potential through continuous R&D [25] Additional Insights - **Market Size for Allergy Treatments**: Approximately 20 million children in China suffer from moderate to severe allergic rhinitis, providing a substantial market opportunity [8] - **Sales Strategy**: Emphasis on professional promotion and market penetration to enhance product visibility and acceptance among healthcare providers [18] This summary encapsulates the key insights from the conference call, highlighting the financial performance, product pipeline, market strategies, and future outlook of Changchun High-tech.

Core Insights - The company reported a significant increase in revenue for the first three quarters of 2025, achieving 208 million yuan, a year-on-year increase of 1562.05% [1] - In Q3 alone, the revenue reached 162 million yuan, marking a year-on-year growth of 1199.88% [1] - The primary drivers of this growth were the sales of the company's first commercial product, Saliqi monoclonal antibody injection (Jinlixi), and the recognition of licensing income from the GR1803 injection's commercialization agreement [1] Revenue and Financial Performance - The overall revenue increase led to a substantial narrowing of the company's losses [1] - The company reported R&D expenditures of approximately 130 million yuan in Q3, with total R&D investments reaching 349 million yuan for the first three quarters [2] Product Development and Clinical Trials - Multiple ongoing projects made significant progress during the reporting period, including the approval and initiation of clinical trials for various products [1][2] - In July, the clinical trial application for Sileweimi monoclonal antibody injection for passive immunity in children and adolescents exposed to suspected rabies virus was approved [1] - In August, clinical trial applications for GR1802 monoclonal antibody injection for seasonal allergic rhinitis in adults and adolescents were approved [1] - In September, clinical trial applications for GR2303 injection for inflammatory bowel disease, GR1803 injection for systemic lupus erythematosus, and GR2301 injection for vitiligo were approved [2] - The new drug application for GR1802 injection for moderate to severe atopic dermatitis was accepted [2]

Core Insights - Frontier Biotech (688221.SH) reported a revenue of 44.73 million yuan for Q3 2025, representing a year-on-year increase of 10.22% [1] - The net profit attributable to shareholders of the listed company was -62.46 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -70.49 million yuan [1]